10X Genomics Refutes Claims of Patent Infringement

10X Genomics Refutes Claims of Patent Infringement

February 12, 2015 02:56 PM Eastern Standard Time

PLEASANTON, Calif.--()--10X Genomics, a provider of an innovative genomics platform, announced today that it is aware of allegations of patent infringement made to the press by RainDance Technologies, Inc. CEO and Co-founder of 10X Genomics, Serge Saxonov, PhD, issued this response:

"We have not been served with a copy of the complaint. However, based upon the assertions in RainDance Technologies' press announcement, we are firmly of the view that our products do not infringe any claims of any of the asserted patents, and to the extent that RainDance is attempting to extend those claims to try to cover our products, we believe that the claims are invalid. We are confident that we will establish both of these points in vigorously defending ourselves in any suit that may arise."

ABOUT 10X GENOMICS

10X Genomics is changing the definition of sequencing by providing an innovative genomics platform that dramatically upgrades the capabilities of existing short read sequencers. The Company does this through a combination of elegant microfluidics, chemistry and bioinformatics. With the 10X Genomics platform, researchers can now find structural variants, haplotypes, and other valuable long range information while leveraging existing sequencing workflows.

Contacts

Chempetitive Group for 10X Genomics
Kena Hudson, 510-908-0966
[email protected]

Suggested Articles

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.